Hi-Acts supports HZDR in launching the nukliD network for the cancer therapy of tomorrow

Radiopharmaceuticals are considered one of the most promising innovations in modern oncology. They combine highly specialized molecules with mildly radioactive substances that specifically target and destroy tumor cells – without unnecessarily affecting healthy tissue. At the same time, they enable precise imaging, giving physicians direct insights into whether the treatment is working.

To bring these innovations from the laboratory to the patient, strong partnerships are essential. The Dresden region stands out as a successful example: research institutions, clinics, and pharmaceutical companies work closely together to develop new agents, evaluate their efficacy, and produce radiopharmaceuticals on a large scale.

The Hi-Acts innovation platform, together with the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), is driving the establishment of the nukliD network. The goal: to strengthen collaboration between science, medicine, and industry – and make the cancer therapy of tomorrow a reality.